Medacs Global Group

medacsglobalgroup.com

Medacs Global Group is one of the leading international healthcare staffing and services companies. Operating under a variety of brands including Medacs Healthcare, Global Medics, Doctors-on-call, Fast Response Healthcare and Litmus Solutions, we provide healthcare recruitment, managed services, occupational health, social care and home care services.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

SKYLINEDX RAISES NEW CAPITAL FROM NOVALIS LIFESCIENCES AND VAN HERK INVESTMENTS

SkylineDx | December 22, 2021

news image

SkylineDx announced it received a capital investment from USA based investment and advisory firm Novalis LifeSciences, and one of Benelux' largest biotech investors Van Herk Investments, to further solidify its position in the USA dermatology diagnostics market. SkylineDx is at a critical growth stage in their development now that the first products are introduced to the USA market, and Novalis LifeSciences has demonstrated impressive successes with their strategic and operational advi...

Read More

MEDICAL

ABC OPENS COMMERCIAL MEL BIOSURFACTANT PRODUCTION IN IRVINE, CA

ABC | May 19, 2022

news image

Advanced BioCatalytics (ABC) is pleased to announce the opening of our new biosurfactant commercial pilot plant in Irvine California. The plant reflects the successful collaboration of the ABC R&D team and Dr. Wenjie Xia, professor of Microbiology at Nankai University in Tianjin China. The commercial pilot plant is the first step in commercial scale up of new glycolipid (biosurfactants) and is the first plant to produce commercial quantities of mannosylerythritol lipids (MEL) in North Americ...

Read More

BOLT BIOTHERAPEUTICS RAISES $93.5 MILLION SERIES C FINANCING

Bolt Biotherapeutics | July 06, 2020

news image

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company developing its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to harness the power of the innate immune system to treat cancer, today announced the closing of an oversubscribed $93.5 million Series C financing. Led by Sofinnova Investments, the Series C financing included participation from new investors RA Capital Management, Surveyor Capital (a Citadel Company), Rock Springs Capital, Samsara BioCapital and Pfi...

Read More

INDUSTRIAL IMPACT

AMBERSTONE BIOSCIENCES SECURES $12 MILLION SERIES A FINANCING TO ADVANCE IMMUNO-ONCOLOGY PIPELINE OF TUMOR MICROENVIRONMENT ACTIVATED THERAPEUTICS

Amberstone Biosciences, Inc. | January 04, 2022

news image

Amberstone Biosciences an emerging biotherapeutics company with unique expertise in conditionally active immunotherapeutics, today announced the completion of a $12 million Series A financing round. The funding was led by Viva BioInnovator, Co-win Ventures and Sinovation Ventures, with additional support from ChangRong Capital, Lifespan Investments and existing shareholders. Amberstone will use the proceeds from the financing to advance its highly differentiated tumor microenviron...

Read More
news image

INDUSTRIAL IMPACT

SKYLINEDX RAISES NEW CAPITAL FROM NOVALIS LIFESCIENCES AND VAN HERK INVESTMENTS

SkylineDx | December 22, 2021

SkylineDx announced it received a capital investment from USA based investment and advisory firm Novalis LifeSciences, and one of Benelux' largest biotech investors Van Herk Investments, to further solidify its position in the USA dermatology diagnostics market. SkylineDx is at a critical growth stage in their development now that the first products are introduced to the USA market, and Novalis LifeSciences has demonstrated impressive successes with their strategic and operational advi...

Read More
news image

MEDICAL

ABC OPENS COMMERCIAL MEL BIOSURFACTANT PRODUCTION IN IRVINE, CA

ABC | May 19, 2022

Advanced BioCatalytics (ABC) is pleased to announce the opening of our new biosurfactant commercial pilot plant in Irvine California. The plant reflects the successful collaboration of the ABC R&D team and Dr. Wenjie Xia, professor of Microbiology at Nankai University in Tianjin China. The commercial pilot plant is the first step in commercial scale up of new glycolipid (biosurfactants) and is the first plant to produce commercial quantities of mannosylerythritol lipids (MEL) in North Americ...

Read More
news image

BOLT BIOTHERAPEUTICS RAISES $93.5 MILLION SERIES C FINANCING

Bolt Biotherapeutics | July 06, 2020

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company developing its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to harness the power of the innate immune system to treat cancer, today announced the closing of an oversubscribed $93.5 million Series C financing. Led by Sofinnova Investments, the Series C financing included participation from new investors RA Capital Management, Surveyor Capital (a Citadel Company), Rock Springs Capital, Samsara BioCapital and Pfi...

Read More
news image

INDUSTRIAL IMPACT

AMBERSTONE BIOSCIENCES SECURES $12 MILLION SERIES A FINANCING TO ADVANCE IMMUNO-ONCOLOGY PIPELINE OF TUMOR MICROENVIRONMENT ACTIVATED THERAPEUTICS

Amberstone Biosciences, Inc. | January 04, 2022

Amberstone Biosciences an emerging biotherapeutics company with unique expertise in conditionally active immunotherapeutics, today announced the completion of a $12 million Series A financing round. The funding was led by Viva BioInnovator, Co-win Ventures and Sinovation Ventures, with additional support from ChangRong Capital, Lifespan Investments and existing shareholders. Amberstone will use the proceeds from the financing to advance its highly differentiated tumor microenviron...

Read More